Athersys Gets An Efficacy Signal In Phase I Safety Study Of MultiStem In Heart Attack
This article was originally published in The Pink Sheet Daily
Executive Summary
Patients in a Phase I study of the adult stem cell product showed encouraging improvement in cardiac function, a surprise efficacy signal in addition to a clean safety profile.
You may also be interested in...
Stem Cell Therapies Walk A Risky Regulatory Road
As the most advanced stem cell therapies, known collectively these days as "regenerative medicine," edge into the clinic, much about the field remains unresolved – including basic regulatory questions and whether the therapies, which hope to restore circulation to ischemic tissue or function to damaged nerves, for example, will even work in humans.
Pfizer Licenses Athersys' Stem Cell Technology For IBD Drug Development
Following the deal news, Athersys' stock price soared during same-day trading.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.